- Home
- SITC vs ERAS Comparison
SITC vs ERAS Comparison
Compare SITC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SITC | ERAS |
|---|---|---|
| Founded | 1965 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.8M | 439.7M |
| IPO Year | 1993 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SITC | ERAS |
|---|---|---|
| Price | $7.18 | $2.90 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $12.63 | $3.50 |
| AVG Volume (30 Days) | 1.2M | ★ 1.6M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | ★ 80.03% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $139,962,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.76 | $1.01 |
| 52 Week High | $15.93 | $3.30 |
Technical Indicators
Market Signals| Indicator | SITC | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 39.43 | 58.37 |
| Support Level | $6.76 | $2.83 |
| Resistance Level | $7.41 | $3.24 |
| Average True Range (ATR) | 0.18 | 0.23 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 57.53 | 61.67 |
Price Performance
Historical ComparisonAbout SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.